SIRT1: Harnessing multiple pathways to hinder NAFLD
Non-alcoholic fatty liver disease (NAFLD) encompasses hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. It is the primary cause of chronic liver disorders, with a high prevalence but no approved treatment. Therefore, it is indispensable to fi...
Main Authors: | Cheng Tian, Rongrong Huang, Ming Xiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-05-01
|
Series: | Pharmacological Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824000999 |
Similar Items
-
SIRT7 and hepatic lipid metabolism
by: Bor Luen eTang
Published: (2015-01-01) -
Rebalancing of mitochondrial homeostasis through an NAD+-SIRT1 pathway preserves intestinal barrier function in severe malnutritionResearch in context
by: Catriona Ling, et al.
Published: (2023-10-01) -
Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway
by: Na Li, et al.
Published: (2023-09-01) -
Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD
by: Lingxuan An, et al.
Published: (2023-01-01) -
SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism
by: Yue Zhang, et al.
Published: (2022-05-01)